Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

Publisher Correction: Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, Broge T, Abbink P, Mercado NB, Chandrashekar A, Jetton D, Peter L, McMahan K, Moseley ET, Bekerman E, Hesselgesser J, Li W, Lewis MG, Alter G, Geleziunas R, Barouch DH.

Nature. 2018 Nov 5. doi: 10.1038/s41586-018-0721-y. [Epub ahead of print]

PMID:
30397346
2.

Antibody and TLR7 agonist delay viral rebound in SHIV-infected monkeys.

Borducchi EN, Liu J, Nkolola JP, Cadena AM, Yu WH, Fischinger S, Broge T, Abbink P, Mercado NB, Chandrashekar A, Jetton D, Peter L, McMahan K, Moseley ET, Bekerman E, Hesselgesser J, Li W, Lewis MG, Alter G, Geleziunas R, Barouch DH.

Nature. 2018 Nov;563(7731):360-364. doi: 10.1038/s41586-018-0600-6. Epub 2018 Oct 3. Erratum in: Nature. 2018 Nov 5;:.

PMID:
30283138
3.

Early antiretroviral therapy limits SIV reservoir establishment to delay or prevent post-treatment viral rebound.

Okoye AA, Hansen SG, Vaidya M, Fukazawa Y, Park H, Duell DM, Lum R, Hughes CM, Ventura AB, Ainslie E, Ford JC, Morrow D, Gilbride RM, Legasse AW, Hesselgesser J, Geleziunas R, Li Y, Oswald K, Shoemaker R, Fast R, Bosche WJ, Borate BR, Edlefsen PT, Axthelm MK, Picker LJ, Lifson JD.

Nat Med. 2018 Sep;24(9):1430-1440. doi: 10.1038/s41591-018-0130-7. Epub 2018 Aug 6.

PMID:
30082858
4.

TLR7 agonists induce transient viremia and reduce the viral reservoir in SIV-infected rhesus macaques on antiretroviral therapy.

Lim SY, Osuna CE, Hraber PT, Hesselgesser J, Gerold JM, Barnes TL, Sanisetty S, Seaman MS, Lewis MG, Geleziunas R, Miller MD, Cihlar T, Lee WA, Hill AL, Whitney JB.

Sci Transl Med. 2018 May 2;10(439). pii: eaao4521. doi: 10.1126/scitranslmed.aao4521.

5.

Blood biomarkers of expressed and inducible HIV-1.

Cillo AR, Hong F, Tsai A, Irrinki A, Kaur J, Sloan DD, Follen M, Geleziunas R, Cihlar T, Win SS, Murry JP, Mellors JW.

AIDS. 2018 Mar 27;32(6):699-708. doi: 10.1097/QAD.0000000000001748.

PMID:
29334544
6.

Ad26/MVA therapeutic vaccination with TLR7 stimulation in SIV-infected rhesus monkeys.

Borducchi EN, Cabral C, Stephenson KE, Liu J, Abbink P, Ng'ang'a D, Nkolola JP, Brinkman AL, Peter L, Lee BC, Jimenez J, Jetton D, Mondesir J, Mojta S, Chandrashekar A, Molloy K, Alter G, Gerold JM, Hill AL, Lewis MG, Pau MG, Schuitemaker H, Hesselgesser J, Geleziunas R, Kim JH, Robb ML, Michael NL, Barouch DH.

Nature. 2016 Dec 8;540(7632):284-287. doi: 10.1038/nature20583. Epub 2016 Nov 9.

7.

A Subset of Latency-Reversing Agents Expose HIV-Infected Resting CD4+ T-Cells to Recognition by Cytotoxic T-Lymphocytes.

Jones RB, Mueller S, O'Connor R, Rimpel K, Sloan DD, Karel D, Wong HC, Jeng EK, Thomas AS, Whitney JB, Lim SY, Kovacs C, Benko E, Karandish S, Huang SH, Buzon MJ, Lichterfeld M, Irrinki A, Murry JP, Tsai A, Yu H, Geleziunas R, Trocha A, Ostrowski MA, Irvine DJ, Walker BD.

PLoS Pathog. 2016 Apr 15;12(4):e1005545. doi: 10.1371/journal.ppat.1005545. eCollection 2016 Apr.

8.

Elevated Plasma Viral Loads in Romidepsin-Treated Simian Immunodeficiency Virus-Infected Rhesus Macaques on Suppressive Combination Antiretroviral Therapy.

Del Prete GQ, Oswald K, Lara A, Shoemaker R, Smedley J, Macallister R, Coalter V, Wiles A, Wiles R, Li Y, Fast R, Kiser R, Lu B, Zheng J, Alvord WG, Trubey CM, Piatak M Jr, Deleage C, Keele BF, Estes JD, Hesselgesser J, Geleziunas R, Lifson JD.

Antimicrob Agents Chemother. 2015 Dec 28;60(3):1560-72. doi: 10.1128/AAC.02625-15.

9.

Short Communication: Comparative Evaluation of Coformulated Injectable Combination Antiretroviral Therapy Regimens in Simian Immunodeficiency Virus-Infected Rhesus Macaques.

Del Prete GQ, Smedley J, Macallister R, Jones GS, Li B, Hattersley J, Zheng J, Piatak M Jr, Keele BF, Hesselgesser J, Geleziunas R, Lifson JD.

AIDS Res Hum Retroviruses. 2016 Feb;32(2):163-8. doi: 10.1089/AID.2015.0130. Epub 2015 Sep 9.

10.

B cell follicle sanctuary permits persistent productive simian immunodeficiency virus infection in elite controllers.

Fukazawa Y, Lum R, Okoye AA, Park H, Matsuda K, Bae JY, Hagen SI, Shoemaker R, Deleage C, Lucero C, Morcock D, Swanson T, Legasse AW, Axthelm MK, Hesselgesser J, Geleziunas R, Hirsch VM, Edlefsen PT, Piatak M Jr, Estes JD, Lifson JD, Picker LJ.

Nat Med. 2015 Feb;21(2):132-9. doi: 10.1038/nm.3781. Epub 2015 Jan 19.

11.

Abyssomicin 2 reactivates latent HIV-1 by a PKC- and HDAC-independent mechanism.

León B, Navarro G, Dickey BJ, Stepan G, Tsai A, Jones GS, Morales ME, Barnes T, Ahmadyar S, Tsiang M, Geleziunas R, Cihlar T, Pagratis N, Tian Y, Yu H, Linington RG.

Org Lett. 2015 Jan 16;17(2):262-5. doi: 10.1021/ol503349y. Epub 2015 Jan 5.

12.

Rapid seeding of the viral reservoir prior to SIV viraemia in rhesus monkeys.

Whitney JB, Hill AL, Sanisetty S, Penaloza-MacMaster P, Liu J, Shetty M, Parenteau L, Cabral C, Shields J, Blackmore S, Smith JY, Brinkman AL, Peter LE, Mathew SI, Smith KM, Borducchi EN, Rosenbloom DI, Lewis MG, Hattersley J, Li B, Hesselgesser J, Geleziunas R, Robb ML, Kim JH, Michael NL, Barouch DH.

Nature. 2014 Aug 7;512(7512):74-7. doi: 10.1038/nature13594. Epub 2014 Jul 20.

13.

Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.

Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, Hesselgesser J, Irrinki A, Murry JP, Stepan G, Stray KM, Tsai A, Yu H, Spindler J, Kearney M, Spina CA, McMahon D, Lalezari J, Sloan D, Mellors J, Geleziunas R, Cihlar T.

PLoS Pathog. 2014 Apr 10;10(4):e1004071. doi: 10.1371/journal.ppat.1004071. eCollection 2014 Apr.

14.

Study of marine natural products including resorcyclic acid lactones from Humicola fuscoatra that reactivate latent HIV-1 expression in an in vitro model of central memory CD4+ T cells.

Mejia EJ, Loveridge ST, Stepan G, Tsai A, Jones GS, Barnes T, White KN, Drašković M, Tenney K, Tsiang M, Geleziunas R, Cihlar T, Pagratis N, Tian Y, Yu H, Crews P.

J Nat Prod. 2014 Mar 28;77(3):618-24. doi: 10.1021/np400889x. Epub 2014 Feb 4.

15.

Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219.

Frey CR, Andrei G, Votruba I, Cannizzaro C, Han B, Fung W, Hung M, Liu X, Geleziunas R, Fiten P, Opdenakker G, Snoeck R, Cihlar T.

Anticancer Res. 2013 May;33(5):1899-912.

PMID:
23645737
16.

New class of HIV-1 integrase (IN) inhibitors with a dual mode of action.

Tsiang M, Jones GS, Niedziela-Majka A, Kan E, Lansdon EB, Huang W, Hung M, Samuel D, Novikov N, Xu Y, Mitchell M, Guo H, Babaoglu K, Liu X, Geleziunas R, Sakowicz R.

J Biol Chem. 2012 Jun 15;287(25):21189-203. doi: 10.1074/jbc.M112.347534. Epub 2012 Apr 25.

17.

Dithiothreitol causes HIV-1 integrase dimer dissociation while agents interacting with the integrase dimer interface promote dimer formation.

Tsiang M, Jones GS, Hung M, Samuel D, Novikov N, Mukund S, Brendza KM, Niedziela-Majka A, Jin D, Liu X, Mitchell M, Sakowicz R, Geleziunas R.

Biochemistry. 2011 Mar 15;50(10):1567-81. doi: 10.1021/bi101504w. Epub 2011 Feb 21.

PMID:
21222490
18.

N1-Alkyl pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Mitchell ML, Son JC, Guo H, Im YA, Cho EJ, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Graupe D, Rhodes G, He GX, Geleziunas R, Xu L, Kim CU.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1589-92. doi: 10.1016/j.bmcl.2010.01.085. Epub 2010 Jan 21.

PMID:
20138513
19.

N1-Heterocyclic pyrimidinediones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.

Mitchell ML, Son JC, Lee IY, Lee CK, Kim HS, Guo H, Wang J, Hayes J, Wang M, Paul A, Lansdon EB, Chen JM, Eisenberg G, Geleziunas R, Xu L, Kim CU.

Bioorg Med Chem Lett. 2010 Mar 1;20(5):1585-8. doi: 10.1016/j.bmcl.2010.01.086. Epub 2010 Jan 21.

PMID:
20137928
20.

Affinity maturation and characterization of a human monoclonal antibody against HIV-1 gp41.

Montgomery DL, Wang YJ, Hrin R, Luftig M, Su B, Miller MD, Wang F, Haytko P, Huang L, Vitelli S, Condra J, Liu X, Hampton R, Carfi A, Pessi A, Bianchi E, Joyce J, Lloyd C, Geleziunas R, Bramhill D, King VM, Finnefrock AC, Strohl W, An Z.

MAbs. 2009 Sep-Oct;1(5):462-74. Epub 2009 Sep 8.

21.

Affinities between the binding partners of the HIV-1 integrase dimer-lens epithelium-derived growth factor (IN dimer-LEDGF) complex.

Tsiang M, Jones GS, Hung M, Mukund S, Han B, Liu X, Babaoglu K, Lansdon E, Chen X, Todd J, Cai T, Pagratis N, Sakowicz R, Geleziunas R.

J Biol Chem. 2009 Nov 27;284(48):33580-99. doi: 10.1074/jbc.M109.040121. Epub 2009 Sep 28.

22.

Catalytically-active complex of HIV-1 integrase with a viral DNA substrate binds anti-integrase drugs.

Alian A, Griner SL, Chiang V, Tsiang M, Jones G, Birkus G, Geleziunas R, Leavitt AD, Stroud RM.

Proc Natl Acad Sci U S A. 2009 May 19;106(20):8192-7. doi: 10.1073/pnas.0811919106. Epub 2009 May 4.

23.

A strategy for selectively shielding portions of a peptide/protein from immune response while maintaining immunogenicity of contiguous epitopes.

Bianchi E, Finotto M, Ingallinella P, Citron M, Hrin R, Lu M, Geleziunas R, Miller MD, Liang X, Pessi A.

Adv Exp Med Biol. 2009;611:359-60. No abstract available.

PMID:
19400225
24.

Preclinical evaluation of GS-9160, a novel inhibitor of human immunodeficiency virus type 1 integrase.

Jones GS, Yu F, Zeynalzadegan A, Hesselgesser J, Chen X, Chen J, Jin H, Kim CU, Wright M, Geleziunas R, Tsiang M.

Antimicrob Agents Chemother. 2009 Mar;53(3):1194-203. doi: 10.1128/AAC.00984-08. Epub 2008 Dec 22.

25.

Structural basis for HIV-1 neutralization by a gp41 fusion intermediate-directed antibody.

Luftig MA, Mattu M, Di Giovine P, Geleziunas R, Hrin R, Barbato G, Bianchi E, Miller MD, Pessi A, Carfí A.

Nat Struct Mol Biol. 2006 Aug;13(8):740-7. Epub 2006 Jul 23.

PMID:
16862157
26.

A human monoclonal antibody neutralizes diverse HIV-1 isolates by binding a critical gp41 epitope.

Miller MD, Geleziunas R, Bianchi E, Lennard S, Hrin R, Zhang H, Lu M, An Z, Ingallinella P, Finotto M, Mattu M, Finnefrock AC, Bramhill D, Cook J, Eckert DM, Hampton R, Patel M, Jarantow S, Joyce J, Ciliberto G, Cortese R, Lu P, Strohl W, Schleif W, McElhaugh M, Lane S, Lloyd C, Lowe D, Osbourn J, Vaughan T, Emini E, Barbato G, Kim PS, Hazuda DJ, Shiver JW, Pessi A.

Proc Natl Acad Sci U S A. 2005 Oct 11;102(41):14759-64. Epub 2005 Oct 3.

27.

Covalent stabilization of coiled coils of the HIV gp41 N region yields extremely potent and broad inhibitors of viral infection.

Bianchi E, Finotto M, Ingallinella P, Hrin R, Carella AV, Hou XS, Schleif WA, Miller MD, Geleziunas R, Pessi A.

Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12903-8. Epub 2005 Aug 29.

28.

Characterization of gp120 and its single-chain derivatives, gp120-CD4D12 and gp120-M9: implications for targeting the CD4i epitope in human immunodeficiency virus vaccine design.

Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, Sinha P, Yadav R, Rashid U, Kennedy S, Eckert D, Geleziunas R, Bramhill D, Schleif W, Liang X, Shiver J.

J Virol. 2005 Feb;79(3):1713-23.

30.

Analysis of the HIV-1 gp41 specific immune response using a multiplexed antibody detection assay.

Opalka D, Pessi A, Bianchi E, Ciliberto G, Schleif W, McElhaugh M, Danzeisen R, Geleziunas R, Miller M, Eckert DM, Bramhill D, Joyce J, Cook J, Magilton W, Shiver J, Emini E, Esser MT.

J Immunol Methods. 2004 Apr;287(1-2):49-65.

PMID:
15099755
31.

N4-acyl-modified D-2',3'-dideoxy-5-fluorocytidine nucleoside analogues with improved antiviral activity.

Shi J, Mathew JS, Tharnish PM, Rachakonda S, Pai SB, Adams M, Grier JP, Gallagher K, Zhang H, Wu JT, Shi G, Geleziunas R, Erickson-Viitanen S, Stuyver L, Otto MJ, Watanabe KA, Schinazi RF.

Antivir Chem Chemother. 2003 Mar;14(2):81-90.

PMID:
12856919
32.
33.

Helicobacter pylori induces RANTES through activation of NF-kappa B.

Mori N, Krensky AM, Geleziunas R, Wada A, Hirayama T, Sasakawa C, Yamamoto N.

Infect Immun. 2003 Jul;71(7):3748-56. Retraction in: Infect Immun. 2011 Jan;79(1):544.

34.

HIV-1 resistance profile of the novel nucleoside reverse transcriptase inhibitor beta-D-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine (Reverset).

Geleziunas R, Gallagher K, Zhang H, Bacheler L, Garber S, Wu JT, Shi G, Otto MJ, Schinazi RF, Erickson-Viitanen S.

Antivir Chem Chemother. 2003 Jan;14(1):49-59.

PMID:
12790516
35.

Cellular pharmacology of D-d4FC, a nucleoside analogue active against drug-resistant HIV.

Erickson-Viitanen S, Wu JT, Shi G, Unger S, King RW, Fish B, Klabe R, Geleziunas R, Gallagher K, Otto MJ, Schinazi RF.

Antivir Chem Chemother. 2003 Jan;14(1):39-47.

PMID:
12790515
36.

Helicobacter pylori induces matrix metalloproteinase-9 through activation of nuclear factor kappaB.

Mori N, Sato H, Hayashibara T, Senba M, Geleziunas R, Wada A, Hirayama T, Yamamoto N.

Gastroenterology. 2003 Apr;124(4):983-92. Erratum in: Gastroenterology. 2010 Oct;139(4):1424.

PMID:
12671895
37.

Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis.

Stoddart CA, Geleziunas R, Ferrell S, Linquist-Stepps V, Moreno ME, Bare C, Xu W, Yonemoto W, Bresnahan PA, McCune JM, Greene WC.

J Virol. 2003 Feb;77(3):2124-33.

38.

Estradiol represses human T-cell leukemia virus type 1 Tax activation of tumor necrosis factor-alpha gene transcription.

Tzagarakis-Foster C, Geleziunas R, Lomri A, An J, Leitman DC.

J Biol Chem. 2002 Nov 22;277(47):44772-7. Epub 2002 Sep 16.

39.

Novel direct detection method for quantitative determination of intracellular nucleoside triphosphates using weak anion exchange liquid chromatography/tandem mass spectrometry.

Shi G, Wu JT, Li Y, Geleziunas R, Gallagher K, Emm T, Olah T, Unger S.

Rapid Commun Mass Spectrom. 2002;16(11):1092-9.

PMID:
11992513
40.

DPC 817: a cytidine nucleoside analog with activity against zidovudine- and lamivudine-resistant viral variants.

Schinazi RF, Mellors J, Bazmi H, Diamond S, Garber S, Gallagher K, Geleziunas R, Klabe R, Pierce M, Rayner M, Wu JT, Zhang H, Hammond J, Bacheler L, Manion DJ, Otto MJ, Stuyver L, Trainor G, Liotta DC, Erickson-Viitanen S.

Antimicrob Agents Chemother. 2002 May;46(5):1394-401.

41.

Human T-cell leukemia virus type I Tax transactivates the matrix metalloproteinase-9 gene: potential role in mediating adult T-cell leukemia invasiveness.

Mori N, Sato H, Hayashibara T, Senba M, Hayashi T, Yamada Y, Kamihira S, Ikeda S, Yamasaki Y, Morikawa S, Tomonaga M, Geleziunas R, Yamamoto N.

Blood. 2002 Feb 15;99(4):1341-9.

42.

HIV-1 Nef inhibits ASK1-dependent death signalling providing a potential mechanism for protecting the infected host cell.

Geleziunas R, Xu W, Takeda K, Ichijo H, Greene WC.

Nature. 2001 Apr 12;410(6830):834-8.

PMID:
11298454
43.
44.

Induction of monocyte chemoattractant protein 1 by Helicobacter pylori involves NF-kappaB.

Mori N, Ueda A, Geleziunas R, Wada A, Hirayama T, Yoshimura T, Yamamoto N.

Infect Immun. 2001 Mar;69(3):1280-6. Retraction in: Infect Immun. 2011 Jan;79(1):543.

45.

NF-kappa B signaling promotes both cell survival and neurite process formation in nerve growth factor-stimulated PC12 cells.

Foehr ED, Lin X, O'Mahony A, Geleziunas R, Bradshaw RA, Greene WC.

J Neurosci. 2000 Oct 15;20(20):7556-63.

46.

Human T-cell leukemia virus type I tax activates transcription of the human monocyte chemoattractant protein-1 gene through two nuclear factor-kappaB sites.

Mori N, Ueda A, Ikeda S, Yamasaki Y, Yamada Y, Tomonaga M, Morikawa S, Geleziunas R, Yoshimura T, Yamamoto N.

Cancer Res. 2000 Sep 1;60(17):4939-45.

47.

The NF-kappa B-inducing kinase induces PC12 cell differentiation and prevents apoptosis.

Foehr ED, Bohuslav J, Chen LF, DeNoronha C, Geleziunas R, Lin X, O'Mahony A, Greene WC.

J Biol Chem. 2000 Nov 3;275(44):34021-4.

48.
49.

Supplemental Content

Loading ...
Support Center